Published in final edited form as:

Pharmacol Biochem Behav. 2010 February ; 94(4): 580–587. doi:10.1016/j.pbb.2009.11.014.

Dopamine, norepinephrine and serotonin transporter gene deletions differentially alter cocaine-induced taste aversion

Jermaine D. Jones^{1,*}, F. Scott Hall², George R. Uhl², and Anthony L. Riley¹

¹Psychopharmacology Laboratory, Department of Psychology, American University, Washington, D.C

²National Institute on Drug Abuse, Intramural Research Program, Molecular Neurobiology Branch, Baltimore, MD

Abstract

Although cocaine is primarily known for its powerful hedonic effects, there is evidence that its affective experience has a notable aversive component that is less well understood. A variety of pharmacological and molecular approaches have implicated enhanced monoamine (MA) neurotransmission in the aversive effects of cocaine. Although numerous studies have yielded data supportive of the role of the monoamines (indirectly and directly), the specific system suggested to be involved differs across studies and paradigms (Freeman *et al.* 2005b; Grupp 1977; Roberts & Fibiger, 1975). Monoamine transporter knockout mice have been useful in the study of many different aspects of cocaine effects relevant to human drug use and addiction, yet an assessment of the effects of deletion of the genes for the dopamine, norepinephrine and serotonin transporters (DAT, NET, SERT) on cocaine's aversive properties has yet to be performed (Uhl *et al.* 2002). In the current investigation, the strength of cocaine-induced aversions was compared among three groups of transgenic mice with deletions of the genes responsible for the production of one of the monoamine transporters. When compared to their respective WT controls, dopamine transporter deletion slightly attenuated cocaine-induced aversion while deletion of SERT or NET resulted in a more significant delay in the onset and strength of cocaine-induced taste aversions. The data lead us to conclude that the action of cocaine to inhibit NET contributes most substantially to its aversive effects, with some involvement of SERT and minimal contribution of DAT.

Keywords

Cocaine; Taste Aversion; DAT; NET; SERT; Knock-Out; Monoamine

1. Introduction

The powerful reinforcing effects of cocaine are believed to underlie its abuse liability (Kuhar *et al.* 1991). Although cocaine's potent hedonic effects dominate its affective experience, reports indicate that cocaine has aversive effects as well (Anthony *et al.* 1989; Blanchard and Blanchard, 1999; Estelles *et al.* 2004; McDougale *et al.* 1994; Rosen and Kosten, 1992; Yang *et al.* 1992). It has been suggested that these aversive effects impact the rewarding effects of cocaine to the extent that they may significantly influence its initial use and subsequent abuse potential (Lynch and Carroll, 2001; Riley and Simpson, 2001; Stolerman and D'Mello, 1981). A number of experimental procedures have been used to

*Corresponding Author: Jermaine Jones, Substance Use Research Center, New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, (212) 543-5151, JermaineDJones@gmail.com.

specifically assay these aversive effects (Ettenburg and Geist, 1991; Koob et al. 1997; Riley and Simpson, 2001). One such procedure is conditioned taste aversion (CTA) learning, a type of Pavlovian conditioning in which a novel taste is paired with the aversive effects of a compound (Garcia et al. 1955). Following repeated exposure to the taste-drug pairing, the subjects will typically avoid consumption of the novel solution (i.e. display a taste aversion), the degree of which is considered to be directly related to the potency of the aversive effects of the drug (Riley and Tuck, 1985; see also www.CTALearning.com).

Manipulation of the aversive affective experience produced by cocaine administration may provide a means of abuse intervention and, accordingly, there has been increased interest in determining the physiological basis of cocaine's aversive properties. Cocaine non-selectively inhibits the reuptake of monoamine neurotransmitters through its blockade of their neuronal plasma membrane transporters, thereby acting as a potent indirect agonist of the norepinephrine (NE), dopamine (DA) and serotonin (5-HT) systems (Taylor and Ho, 1978). Although cocaine has multiple sites of action, its effects upon dopaminergic neurotransmission have long been thought to mediate most of its behavioral effects, most notably, locomotor stimulation and reward (Kuhar et al., 1991).

Interestingly, research from a variety of pharmacological and molecular approaches has implicated actions upon these systems as the basis of the aversive effects of cocaine as well (Freeman et al. 2005a; Goudie and Thorton, 1975; Grupp, 1977; Roberts and Fibiger, 1975; Serafine and Riley, 2009). Direct comparisons of the taste aversions produced by selective monoamine transporter inhibitors to those produced by cocaine have repeatedly observed that only NET inhibitors are capable of matching the aversive potency of cocaine (Freeman et al., 2005b, Jones et al., 2009), although results from other approaches have yielded conflicting results (Freeman et al., 2008; Serafine and Riley, 2009). The majority of previous research assessing the specific neurochemistry of cocaine-induced aversions has been pharmacological in nature (either by mimicking or antagonizing cocaine-induced effects) and with this approach comes unique methodological concerns (i.e. selectivity of the pharmacological agent employed). For that matter, one of the fundamental questions regarding many of the effects of cocaine is whether multiple sites of action contribute, or can contribute, to its effects.

Transgenic techniques present an alternative approach to help elucidate the specific roles of DA, 5-HT and NE transmission in cocaine-induced CTA. These techniques, particularly gene knockouts (KO), have proven useful in investigations of the biochemical basis underlying the behavioral effects of many commonly abused drugs (Cordero-Erausquin et al., 2000; Giros et al., 1996; Hall et al., 2001; Miner et al. 1995, Pan et al., 2009; Sora et al., 1998; Thomsen et al. 2009; Tzavara et al. 2009). To date, research utilizing transgenic mice lacking the monoamine transporters (DAT, NET and/or SERT) has primarily been used to assess their roles in the ability of cocaine to modulate reward and locomotor behavior (Chen et al. 2006; Hall et al. 2002; Hall et al, In Press; Giros et al. 1996; Rocha et al. 2003; Sora et al. 1998, 2001; Thomsen et al., 2009; Xu et al. 2000a). However, this work has indirectly implicated the contributions of the MA systems in aversive effects of cocaine as well. Specifically, KO mice lacking either NET or SERT display enhanced cocaine-induced place preferences (CPP), an effect that is even further enhanced in NET/SERT double KO mice (Hall et al., 2002, see discussion in Hall et al., 2004). This suggests that in wildtype subjects with intact transporters, cocaine induced elevation in NE and/or 5-HT may be aversive and, thus, counteracts the normally rewarding effects of cocaine mediated elsewhere (Uhl et al., 2002). Given that such work only indirectly addresses the role of these genes in drug-induced aversions, a direct assessment of the ability of subjects with DAT, NET or SERT gene deletions to acquire aversions is needed. Accordingly, in the following investigation cocaine-induced conditioned taste aversions were assessed in groups of KO mice with

lifelong deletions of the genes responsible for the production of either the DA, NE or 5-HT transporters using homozygous (−/−) monoamine transporter KO mice (DAT KO, SERT KO, and NET KO) compared to wildtype littermate controls.

2. Methods and Materials

2.1 Subjects

The DAT, SERT and NET knockout mice and wildtype littermate controls used in these experiments were bred from DAT/SERT and NET/SERT double knockout lines that have been previously described (Sora et al. 2001; Hall et al. 2002). These double knockout lines had been derived by crosses of the original single knockout lines (Bengel et al. 1998; Sora et al. 1998; Xu et al. 2000). Thus, these gene knockouts were expressed on a mixed C57BL/6J-129 background (ES cells were from R1, J1, and AK7 cell lines from different 129 sub-strains; see Jackson Labs for details: <http://jaxmice.jax.org/jaxnotes/archive/481e.html>). Although the lines used to produce these mice were double knockout lines, only single gene knockouts were used in these experiments. DAT KO and SERT KO mice were from the DAT/SERT double knockout line, and NET KO mice were from the NET/SERT double knockout line. Therefore separate WT controls were needed for the NET KO mice (designated NET WT), but the same WT controls were used for both DAT KO and SERT KO mice (designated DAT/SERT WT). All subjects were bred from heterozygote crosses producing −/− and +/+ littermates. Mice were genotyped using polymerase chain reaction (PCR) amplification using two internal primers, one targeted at the knockout insertion sequence and one targeted at the WT gene, and one external primer, which generated two products identifying the WT and KO genes. The DAT and SERT transgenic knockout insertion sequences contained a neomycin gene (NEO), while the NET KO contained a green fluorescent protein gene insert (GFP). PCR using TSG DNA polymerase (Bio Basic, Inc., Canada) was performed on DNA that was eluted from tail tip fragments after digestion overnight in Protease K. For DAT genotyping the external primer (AGT GTG TGC AGG GCA TGG TGT A) and the WT primer (TAG GCA CTG CTG ACG ATG ACT G) produced a 500 bp band, while the external primer and the NEO primer (CTC GTC GTG ACC CAT GGC GAT) produced a 600 bp band. For SERT genotyping the external primer (GCT CTC AGT CTT GTC TCC ATA AC) and the WT primer (TGC TGA CTG GAG TAC AGG CTA G) produced a 620 bp band, while the external primer and the NEO primer (CTC GTC GTG ACC CAT GGC GAT) produced an 800 bp band. For NET genotyping the external primer (GCT CTG TCC CTG TGC TTC ACG) and the WT primer (TGA GGC CTA AGC TGG AGC TCG) produced a 600 bp band, while the external primer and the GFP primer (CGG TGA ACA GCT CCT CGC CC) produced a 470 bp band. A total of 204 subjects were utilized, and as is common for most transgenic studies male and female mice of each genotype were employed. Since no sex differences were observed the data presented here has been collapsed across gender. At the time of testing all subjects were between the ages of 12–20 weeks. Each genotype/dose group consisted of between 8–12 mice with subjects only being used in one condition.

2.2 Apparatus/Housing

All subjects were individually housed in Plexiglas bins (44.5 × 23 × 20 cm) fitted with wire-grated tops. Subjects were maintained under a 12:12 LD cycle (lights on at 0800h) and at an ambient temperature of 23 °C. Harland Rat and Mouse Laboratory Diet was available *ad libitum* throughout the experiment. Water was available *ad libitum* until the experimental procedures were initiated (see below). All experimental procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council, 1996) and the Guidelines for the Care and Use of Mammals in Neuroscience and

Behavioral Research (National Research Council, 2003) and were approved by the American University Institutional Animal Care and Use Committee.

2.3 Drugs and Solutions

Cocaine hydrochloride (HCl) (generously supplied by the National Institute on Drug Abuse) was dissolved in saline and subcutaneously (sc) administered in a concentration of 10 mg/ml (cocaine doses expressed as the salt).

2.4 Drug Conditioning

On Day 1 of this phase, subjects were allowed 1-h access to a novel saccharin solution during their scheduled fluid-access period. Based on their level of saccharin consumption, subjects of each genotype were assigned to one of four drug conditions. This procedure ensures that there were no initial differences in consumption, between drug conditions, within each genotype. Within 10–15 min following saccharin access, subjects were injected sc with one of four doses of cocaine (0, 18, 32 and 50 mg/kg). This ¼ log function has been shown to represent a wide range of cocaine's aversive effects within this preparation, producing significant dose-dependent aversions in both rats and mice (Busse *et al.* 2005; Freeman *et al.* 2005a; Jones *et al.*, 2009). The 0 mg/kg dose consisted of a vehicle injection of saline which was isovolumetric with the highest dose of drug. The different drug doses and genotypes resulted in the following groups: DAT/SERT WT (0, 18, 32, 50 mg/kg); NET WT (0, 18, 32, 50 mg/kg); DAT KO (0, 18, 32, 50 mg/kg); SERT KO (0, 18, 32, 50 mg/kg); NET KO (0, 18, 32, 50 mg/kg). On the three days following each conditioning day, all subjects were allowed 1-h access to water without drug administration. This alternating procedure of conditioning/water recovery was repeated for a total of four complete cycles.

2.5 Statistical Analysis

Analysis of Variance (ANOVA) was used to compare absolute saccharin consumption following conditioning with saline, in order to examine baseline differences in saccharin preference among the 5 genotypes. In order to further control for significant baseline differences observed in the initial ANOVA (addressed in more detail in the results section) the data were transformed into percent shift from baseline scores $[(\text{TRIAL } \{2, 3, 4\} - 100) / \text{TRIAL } 1 - 100 = \% \text{ Shift}]$.

For subsequent analyses, comparisons of the degree of aversions (as measured by % shift score) were made using Repeated Measures Analysis of Variance (ANOVA). The between-subjects factors for each of these analyses were DOSE (0, 18, 32, 50) and/or GENOTYPE (D/S WT, DAT KO, SERT KO, NET WT, NET KO) and the within-subjects factor was TRIAL(2,3,4). To determine the basis of significant effects in the overall ANOVA, separate analyses compared the two wild-type strains, as well as comparing the knockouts to their respective wild-type littermates. When significant effects were observed in these ANOVA follow-up ANOVAs were used to compare saccharin consumption at each trial, for each dose of drug. When necessary, Tukey's HSD post-hoc tests were utilized to specify between genotype and/or trial differences.

3. Results

3.1 Absolute Saccharin Consumption Comparison between D/S WT and NET WT

Between the two WT conditions, ANOVA revealed significant main effects of Trial $F(3, 225) = 67.92, p < 0.001$, Dose $F(3, 75) = 26.97, p < 0.001$ and Genotype $F(1, 75) = 5.91, p < 0.05$. Along with significant Trial $\times$ Dose $F(9, 225) = 10.71, p < 0.01$ and Trial $\times$ Genotype interactions $F(3, 225) = 5.55, p < 0.01$. Subsequent comparisons were made

utilizing a % shift score in order to control for background strain differences observed between the two WT conditions in this analysis (Figure 1).

Differences in consumption following saline-only administration (Figure 2) again highlight differences in saccharin-solution preference or neophobia among all 5 genotypes further validating the necessity of the percent shift transformation.

3.2 Percent Shift Comparisons among all 5 Genotypes

An initial analysis using Repeated-Measures ANOVA compared % shift scores across TRIALS, DOSES and GENOTYPES. This analysis found significant main effects for TRIAL: $F(2, 348) = 20.42$, $p < 0.001$, DOSE: $F(3, 174) = 28.66$, $p < 0.001$ and GENOTYPE: $F(4, 174) = 3.92$, $p < 0.005$; along with significant TRIAL $\times$ DOSE: $F(6, 348) = 8.79$, $p < 0.001$ and TRIAL $\times$ GENOTYPE: $F(8, 348) = 1.98$, $p < 0.05$ interactions. Subsequent analyses revealed the nature of the overall effect of GENOTYPE and the GENOTYPE $\times$ TRIAL interaction shown in this initial analysis, part of which was due to differences between the two lines due to background strain differences. These differences necessitated separate comparisons of DAT KO, SERT KO and NET KO mice to their respective WT controls.

3.3 Percent Shift Comparison between D/S WT and NET WT

ANOVA comparing % shift scores between the D/S WT and NET WT groups were performed in order to assess potential background strain differences between the two lines (Figure 3). This analysis revealed significant main effects of GENOTYPE [$F(1, 75) = 3.99$, $p < 0.05$], TRIAL [$F(2, 15) = 18.17$, $p < 0.001$] and DOSE [$F(3, 75) = 28.59$, $p < 0.001$]. Significant interactions were also observed for GENOTYPE $\times$ DOSE [$F(3, 75) = 2.82$, $p < 0.05$], TRIAL $\times$ DOSE [$F(6, 150) = 5.38$, $p < 0.001$], and the GENOTYPE $\times$ TRIAL interaction also approached significance [$F(2, 150) = 2.98$, $p = 0.057$]. Differences between these two groups further demonstrate the potential confounding effects of comparing genotypes which do not share the same genetic background. Planned comparisons between genotypes for each trial found no significant differences between the two groups for Trial 2 with any of the drug doses tested. Yet at Trial 3 the degree of suppression in saccharin consumption was smaller in the NET WT group than the D/S WT group following conditioning with saline ($p < 0.001$), 18 ($p < 0.001$) and 32 ($p < 0.05$) mg/kg of drug. For the final trial (Trial 4) the % decrease from Trial 1 was smaller in the NET WT group following conditioning with saline ($p < 0.001$) and 18 ($p < 0.05$) mg/kg of cocaine. Thus, in order to control for the confounding influence of background strain, the analyses of the effects of NET, SERT and DAT knockout reported below were only made between genotypes with a common genetic background (e.g. D/S background = D/S WT, DAT KO and SERT KO; and NET background = NET WT and NET KO).

3.4 Percent Shift Comparisons among D/S WT, DAT KO and SERT KO Mice

In the typical CTA procedure an aversion can be defined in two ways, either as a significant suppression in comparison to a saline-conditioned group on a particular trial or a significant suppression on subsequent trials when compared to the baseline level of consumption on the first trial. Omnibus comparison of the % shift in saccharin consumption across TRIAL, DOSE and GENOTYPE found significant main effects of GENOTYPE $F(2, 112) = 4.97$, $p < 0.01$, DOSE $F(3, 112) = 21.68$, $p < 0.001$, and TRIAL $F(2, 112) = 21.71$, $p < 0.001$, as well as a significant TRIAL $\times$ DOSE interaction $F(6, 224) = 8.66$, $p < 0.001$. As such, planned analyses sought to determine whether there were differences in the onset and strength of the aversions among the D/S background groups (Figure 4). These analyses compared consumption among the 4 dose conditions, at each trial, as well as across trials for each dose.

In order to examine differences in the rate of aversion development among the three genotypes the first analysis compared saccharin consumption following conditioning with each active DOSE of cocaine (18, 32, 50 mg/kg) versus saline (0 mg/kg) at each TRIAL (separately for each genotype). On Trial 2 (% shift for Trial 1 was 0 for all groups) a significant suppression in saccharin consumption was observed in D/S WT subjects conditioned with the highest dose versus saline treated subjects (50 mg/kg; $p < 0.05$). For this trial DAT KO and SERT KO groups conditioned with 18, 32 and 50 mg/kg of cocaine did not differ significantly in their consumption from subjects of their same genotype conditioned with saline. At Trial 3 conditioning with 32 mg/kg cocaine significantly reduced saccharin consumption in D/S WT mice ($p < 0.001$) and DAT KO mice ($p < 0.05$), but not SERT KO mice, versus saline-treated controls. Similarly for Trial 3 the 50 mg/kg dose significantly reduced saccharin in these two genotypes (D/S WT: $p < 0.001$, DAT KO $p < 0.05$). The effects of the 32 and 50 mg/kg doses in SERT KO subjects were not significant for Trial 3. For Trial 4 the lowest dose of cocaine (18 mg/kg) significantly reduced saccharin consumption in the D/S WT group ($p < 0.01$), but not in either of the KO groups. For Trial 4 the 32 mg/kg dose produced a significant suppression of consumption in all three genotypes (D/S WT: $p < 0.001$, DAT KO: $p < 0.005$, and SERT KO: $p < 0.05$), as did the highest dose of cocaine (D/S WT: $p < 0.001$, DAT KO: $p < 0.01$, SERT KO: $p < 0.01$).

In order to compare differences in the strength (degree of suppression) of cocaine-induced aversions, further analysis compared the degree of suppression in each of the three GENOTYPES (D/S WT, DAT KO, SERT KO) at each TRIAL (separately for each DOSE). This analysis found that significant differences among the three groups were only observed in response to conditioning with 50 mg/kg of cocaine at Trial 3. For this trial, the percent decrease from baseline for both SERT KO ($p < 0.05$) and DAT KO ($p < 0.05$) mice was significantly smaller than for D/S WT mice (Figure 4). No other dose comparisons were significant. When conditioned with the same dose of drug, the DAT KO and SERT KO groups never differed significantly from each other at any trial.

3. 5 Percent Shift Comparisons between NET WT and NET KO Mice

Again, based upon the results of the omnibus ANOVA [GENOTYPE $F(1, 62) = 2.97$, $p < 0.05$; DOSE $F(3, 62) = 10.06$ $p < 0.001$; TRIAL $F(2, 124) = 4.58$ $p < 0.05$; TRIAL $\times$ DOSE; $F(6, 124) = 2.63$, $p < 0.05$] planned analyses sought to determine if there were differences in the onset and strength of the aversions between the NET WT and NET KO groups (Figure 5). In order to assess differences in the onset of the aversions between the two genotypes we first compared saccharin consumption following conditioning with each active DOSE of cocaine (18, 32, 50 mg/kg) versus saline (0 mg/kg) at each TRIAL (separately for each genotype). At Trial 2 the largest dose of cocaine (50 mg/kg) significantly suppressed saccharin consumption compared to saline treatment in NET WT mice ($p < 0.01$). None of the cocaine doses had significant effects in NET KO subjects in Trial 2. On Trial 3, only the 50 mg/kg dose significantly suppressed saccharin consumption within NET WT mice ($p < 0.01$), while again cocaine was ineffective in NET KO subjects at all doses. Similarly in Trial 4, significant suppression of saccharin consumption was only observed in response to conditioning with the largest cocaine dose, but this was observed in both NET WT ($p < 0.001$) and KO mice ($p < 0.05$).

In order to examine differences in the strength of cocaine-induced taste aversion, planned comparisons assessed the degree of suppression produced between the two GENOTYPES (NET WT and NET KO) at each TRIAL (separately for each DOSE). This analysis revealed significant GENOTYPE differences in saccharin consumption following conditioning with 18 mg/kg (Trial 2: $p < 0.05$) and 50 mg/kg (Trial 3: $p < 0.05$) of cocaine (Figure 5). For both of these trials, the percent decrease in suppression produced by cocaine was significantly smaller in NET KO mice.

4. Discussion

Transgenic manipulations of the monoamine transporters, as well as other monoamine system related genes, have proven to be an effective tool in investigating the biological basis of many cocaine-mediated effects (for a review, see Hall et al., 2004). Previous studies, not surprisingly, have concentrated upon the rewarding or reinforcing effects of cocaine. The results reported here are the first to directly examine the aversive effects of cocaine in monoamine transporter knockout mice, although the potential importance of cocaine aversion for explaining the effects of SERT KO and NET KO on cocaine CPP have been hypothesized previously (Uhl et al., 2002). In the current study, individual groups of monoamine transporter KO mice were conditioned with various doses of cocaine in order to assess the effects of DA, NE and 5-HT transporter deletions on the acquisition of cocaine-induced CTA.

Since the knockout mice used here were from two separate lines, it was important to consider the genetic background of the control mice and to compare the knockouts to littermate controls. Reduced cocaine CTA was observed overall for NET WT mice compared to D/S WT mice. For the D/S WT group, all three doses of cocaine induced significant aversions in a dose-dependent manner when compared to saline-treated controls. DAT deletion slightly reduced the strength of cocaine-induced CTA. Unlike their WT controls, conditioning with 18 mg/kg of cocaine did not produce a significant suppression of saccharin consumption in the DAT KO group and aversions were only observed in response to conditioning with the two highest doses. SERT transporter deletion appeared to produce a somewhat greater reduction in the strength of cocaine CTA. In SERT KO mice, only the highest dose of cocaine (50 mg/kg) was able to significantly reduce saccharin consumption. Although direct dose and trial comparisons between the DAT and SERT KO mice did not identify any differences in the strength of the cocaine-induced aversions, there was a delay in the development of cocaine-induced aversions in SERT KO mice compared to both D/S WT mice and DAT KO mice, suggesting that they were less sensitive to the aversive properties of cocaine than either of these groups. Although the highest conditioning dose induced significant aversions in all three genotypes, the rate of acquisition of these aversions differed significantly between genotypes. The aversion developed most rapidly in the D/S WT mice (trial 2), compared to DAT KO (trial 3) and SERT KO mice (trial 4). Additionally the strength of the aversion produced by this dose of cocaine was reduced in both knockout groups, but only for trial 3.

As mentioned above, when compared to D/S WT mice, decreased sensitivity to the aversive properties of cocaine was observed in NET WT mice. Specifically, NET WT mice exhibited delayed rate of acquisition and reduced strength of their aversions. These differences between the lines of wild-type mice is not surprising as previous studies have observed differences in cocaine CTA between C57 and 129 mouse strains (de Bruin et al., 2006; Randall-Thompson et al., 2005). In NET WT and NET KO mice, suppression of saccharin consumption, compared to saline treated mice was only observed following conditioning with 50 mg/kg cocaine. For the WT group, suppression began at an earlier point during conditioning (trial 2) and persisted throughout all subsequent trials, while in NET KO mice decreased consumption was only observed for final trial. Additionally, the strength of the suppression in saccharin consumption produced by cocaine was reduced in NET KO mice compared to WT mice. At multiple trials saccharin consumption was considerably more suppressed by pairing with cocaine in WT mice. Thus, in contrast to the relatively small effects observed for DAT KO or SERT KO, NET KO produced relatively large reductions in the ability of cocaine to induce a taste aversion.

These experiments, therefore, demonstrate that DAT, SERT and NET gene deletion all altered the sensitivity to the aversive effects of cocaine, although to far different degrees. Only a minimal effect of DAT KO was found, a somewhat greater effect of SERT KO, and the largest effect produced by NET KO.

One of the consequences of the way that most knockouts were initially made, and maintained, on a mixed genetic background is that different C57 and 129 alleles have fixated in different lines through random drift in each strain. Although an alternative would be to produce congenic lines, we have found that the mortality observed in DAT KO mice (Sora, et al., 1998) is dramatically increased when this knockout is placed on a C57 background (Hall, Sora and Uhl, unpublished observations). In any case, regardless of the genetic background of the mice, and whether it is mixed or congenic, littermate comparisons allow determination of the effects of the knockout (although it is quite possible that the effects of the knockout itself might vary with genetic background, the only resolution to this dilemma being to examine the effects of the knockout on multiple congenic backgrounds).

Based on these findings, it appears that inhibition of the norepinephrine transporter contributes most substantially to the aversive effects of cocaine in the CTA paradigm, with some involvement of SERT inhibition and the least contribution by DAT inhibition. Research characterizing the behavioral phenotypes of NET KO and SERT KO mice provides additional support for this hypothesis. Microdialysis studies have correlated increased NE transmission with depression (Mokrani et al. 1997). Forced-swim and tail suspension tests also reveal changes in depressant-like behavior in both NET KO and SERT KO mice; although these effects are dependent on strain and other considerations (Dziedzicka-Wasylewska et al. 2006; Holmes et al. 2002; Perona et al. 2008; Xu et al. 2000). SERT KO mice also have impaired stress coping and fear conditioning (Wellman et al. 2007), and Holmes and colleagues (2002; 2003a,b) reported that SERT KO mice exhibit exaggerated neuroendocrine and adreno medullary responses to stress and potentiated anxiety-like behavior in response to novelty as well as in the elevated plus maze, the light-dark box and the open field. Researchers often attribute the elevated anxiety-like behavioral phenotypes found in these models to elevated extracellular 5-HT and/or NE (Kalueff et al. 2006), although some studies have concluded that antidepressant-like effects result from increased 5-HT and NE transmission (Gainetdinov and Caron, 2003; Perona et al., 2008).

Some other findings in transgenic mouse models support these conclusions. 5-HT_{1B} and 5-HT_{2C} receptor KO mice have both been shown to self-administer cocaine at higher levels in comparison to wild-type controls (Pattij et al., 2003; Rocha et al., 2002). One interpretation of these results may be that this removes an aversive component of cocaine's hedonic effects mediated by these receptors. A similar conclusion has been drawn to explain the slight increase in cocaine self-administration observed in dopamine D₂ receptor knockout mice (Caine et al., 2002).

Although it would appear that increases in 5-HT neurotransmission may be involved in the aversive effects of cocaine, there is also evidence that enhanced 5-HT neurotransmission is an essential component of cocaine's rewarding effects as well. Elimination of the dopamine transporter has not been shown to abolish the rewarding effects of cocaine in most studies (Giros et al. 1996; Medvedev et al. 2005; Rocha et al. 1998; Sora et al. 1998), but deletion of both DAT and SERT do abolish cocaine conditioned place preference (Sora et al., 2001) and cocaine conditioned locomotion (Hall et al. In Press). This finding strongly suggests that enhanced 5-HT neurotransmission contributes to cocaine reward (Sora et al. 2001), at least under some circumstances. In other circumstances it appears that much of the rewarding effects of cocaine are mediated by DAT. Inactivating cocaine binding to DAT was sufficient to eliminate cocaine conditioned place preference (Chen et al., 2006), and a more detailed

study of cocaine self-administration demonstrated that it was largely eliminated in the same line that had previously been shown to have normal cocaine CPP (Thomsen et al., 2009). Thus, it would appear that 5-HT neurotransmission contributes to both rewarding and aversive affective components of cocaine.

In a previous study from this laboratory, DAT was implicated in the aversive effects of cocaine. Randall-Thompson and colleagues (2005) observed attenuated cocaine-induced taste aversion, but intact cocaine-induced place preference, in DAT knockout mice. In the current study, a small attenuation in the magnitude and onset of cocaine CTA was also found in DAT KO mice, although the ED50 values for D/S WT and DAT KO groups were only marginally different, suggesting that the difference between the two groups was minimal. However, the observation by Randall-Thompson and colleagues is also difficult to compare to the current, more extensive examination of cocaine CTA, due to a number of methodological differences from the present investigation. That study examined only one dose of cocaine and also used a combined CPP/CTA design. In this combined procedure, subjects were allowed access to saccharin, injected with cocaine and put in a place preference apparatus, i.e., taste aversion and place preference conditioning was examined concurrently in these subjects. It is unknown to what extent this concurrent conditioning may have impacted the likelihood of acquiring the taste aversion in the KO mice. It is interesting to note that some control subjects in the combined design developed a preference for areas paired with saline (likely due to its association with the previously presented saccharin solution), suggesting that some interaction of the aversion and place preference conditioning may have impacted the overall results.

Returning to a consideration of the present findings, although single transporter deletions were effective at attenuating the aversive effects of cocaine, cocaine CTA was not eliminated with any single gene deletion. It may be that the actions of cocaine upon multiple transporters contribute to cocaine-induced taste aversions; an implication supported by research on the rewarding aspects of cocaine, discussed above. If the actions of cocaine at multiple transporters constitute the basis of its aversive effects, then it might be expected that cocaine-induced taste aversions could only be attenuated (and not eliminated) by single transporter deletions. Our research, and that of others, suggests that deletion of both the NET and SERT genes would have the most influence upon the aversive properties of cocaine and their combined deletion may more substantially diminish cocaine CTA.

Another possibility why single transporter deletions may not have completely eliminated the acquisition of cocaine-induced taste aversions may be the adaptations in these systems that have been shown to occur in response to transporter deletion (Benoit-Marand et al., 2000; Fabre et al. 2000; Jones et al. 1999; Kim et al. 2005). Considerable biochemical changes have been observed in all three monoamine transporter knockouts, including altered receptor expression, changes in neurotransmitter regulation and decreased autoreceptor function (for summary, see Gainetdinov and Caron, 2003). Such adaptations have been suggested to be responsible for the maintenance of cocaine-mediated behaviors including CPP and self-administration in DAT KO mice (Rocha et al. 2003; Sora 1998). Because of these potential compensatory alterations in the normal mechanisms underlying reward and aversion in DAT, NET and SERT KO mice the effects observed in these mice may not necessarily reflect the mechanisms controlling the aversive effects of cocaine in WT mice; although it raises the possibility that there may be individual differences in the basis of cocaine between individuals. Evidence that such profound alterations occur includes evidence that selective serotonin (fluoxetine) and norepinephrine (nisoxetine) inhibitors gain reinforcing properties in DAT KO mice that are not found in WT mice (Hall et al., 2002). However, a notable consideration is that the findings obtained here using gene knockouts are in agreement with

most pharmacological research utilizing CTA (Jones et al., 2009; Serafine and Riley, 2009 though see Freeman et al., 2008 for conflicting results).

The present work assumes that the suppression of consumption of cocaine-associated solutions reflects the aversive effects of cocaine. It should be noted that others have argued that such avoidance is due instead to the rewarding effects of cocaine (see Grigson, 1996). According to this “reward comparison hypothesis” avoidance of solutions associated with drugs such as cocaine is a function of negative contrast to the subsequently administered cocaine. Such a contrast results in the avoidance of the consumption of saccharin. The results of this study fail to support this interpretation which would predict that NET and SERT gene deletion, which enhance cocaine reward, would enhance and not attenuate the aversive effects of cocaine as observed here. Furthermore, if cocaine’s rewarding effects were the basis of its ability to induce taste aversions, DAT gene deletion should have produced the strongest attenuation, yet this manipulation was the least effective of the three.

From consideration of the present results, it is clear that the ability of cocaine to induce CTA is primarily mediated by its effects on NET, with some contribution by SERT, and perhaps a minor contribution by DAT. Future studies may confirm this multi-transporter hypothesis using multiple transporter knockouts, as was done for cocaine CPP (Sora et al., 2001). However, in order to better define the relative contributions of each system, other investigations may benefit from targeting specific monoamine receptors. Transporter deletion affects all of the neurons receiving those monoaminergic inputs that express that transporter, whereas receptor knockouts would only affect a subset expressing that particular receptor, likely to be expressed in specific brain areas, and involved in a subset of the actions of cocaine. There is compelling evidence suggesting that there are substantial and conflicting ways in which different receptors for the same neurotransmitter can contribute to the affective profile of a compound (Carey et al. 2005; Di Chiara et al. 2004; Parsons et al. 1998; Pruitt et al. 1995; Rocha et al. 2005; Shippenberg et al. 1993; Woolverton and Kleven, 1988). Collectively, these data, along with studies of the mechanisms underlying the rewarding effects of cocaine, indicate that varying the proportion of the monoaminergic effects at each of the three monoamine transporters is an important and critical determinant of the relative rewarding and aversive consequences of monoamine transporter blockers that could lead to significantly different affective profiles for different drugs, or between individuals that differ in the functioning of these transporters.

Acknowledgments

This research was supported by a grant from the Mellon Foundation (ALR), and also, in part, by the Intramural Research Program of the National Institute on Drug Abuse (FSH, GRU). Requests for reprints should be sent to Jermaine Jones, Substance Use Research Center, New York State Psychiatric Institute, 1051 Riverside Dr. New York, NY 10032

References

- Anthony JC, Tien AY, Petronis KR. Epidemiological evidence on cocaine use and panic attack. *Am J Epidemiol.* 1989; 129:543–549. [PubMed: 2916547]
- Bengel D, Murphy DL, Andrews AM, Wichems CH, Feltner D, Heils A, Mossner R, Westphal H, Lesch KP. Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice. *Mol Pharmacol.* 1998; 53:649–655. [PubMed: 9547354]
- Benoit-Marand M, Jaber M, Gonon F. Release and elimination of dopamine in vivo in mice lacking the dopamine transporter: functional consequences. *Eur J Neurosci.* 2000; 12:2985–2992. [PubMed: 10971639]

- Blanchard DC, Blanchard RJ. Cocaine potentiates the defensive behaviors related to fear and anxiety. *Neurosci Biobehav Revs.* 1999; 23:981–991. [PubMed: 10580312]
- Busse GD, Freeman KB, Riley AL. The interaction of sex and route of administration in cocaine-induced taste aversion. *Pharmacol Biochem Behav.* 2005; 81:814–820. [PubMed: 16005058]
- Caine SB, Negus SS, Mello NK, Patel S, Bristow L, Kulagowski J, Vallone D, Saiardi A, Borrelli E. Role of dopamine D₂-like receptors in cocaine self-administration: studies with D₂ receptor mutant mice and novel D₂ receptor antagonists. *J Neurosci.* 2002; 22:2977–2988. [PubMed: 11923462]
- Carey RJ, DePalma G, Damianopoulos E, Shanahan A, Müller CP, Huston JP. Evidence that the 5-HT_{1A} autoreceptor is an important pharmacological target for the modulation of cocaine behavioral stimulant effects. *Brain Res.* 2005; 1034:162–171. [PubMed: 15713268]
- Chen R, Tilley MR, Wei H, Zhou F, Zhou FM, Ching S, Quan N, Stephens RL, Hill ER, Nottoli T, Han DD, Gu HH. Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. *Proc Natl Acad Sci U S A.* 2006; 103:9333–9338. [PubMed: 16754872]
- Cordero-Erausquin M, Marubio LM, Klink R, Changeux JP. Nicotinic receptor function: new perspectives from knockout mice. *Trends Pharmacol Sci.* 2000; 21:211–217. [PubMed: 10838608]
- de Bruin N, Mahieu M, Patel T, Willems R, Lesage A, Megens A. Performance of F2 B6x129 hybrid mice in the Morris water maze, latent inhibition and prepulse inhibition paradigms: Comparison with C57Bl/6J and 129sv inbred mice. *Behav Brain Res.* 2006; 172:122–134. [PubMed: 16764948]
- Di Chiara G, Bassareo V, Fenu S, De Luca MA, Spina L, Cadoni C, Acquas E, Carboni E, Valentini V, Lecca D. Dopamine and drug addiction: the nucleus accumbens shell connection. *Neuropharmacol.* 2004; 47:227–241.
- Dziedzicka-Wasylewska M, Faron-Górecka A, Kuśmider M, Drozdowska E, Rogóż Z, Siwanowicz J, Caron MG, Bönisch H. Effect of antidepressant drugs in mice lacking the norepinephrine transporter. *Neuropsychopharmacol.* 2006; 31:2424–2432.
- Estelles J, Rodriguez-Arias M, Aquilar MA, Minarro J. Social behavioral profile of cocaine in isolated and group male mice. *Drug Alcohol Depend.* 2004; 76:115–123. [PubMed: 15488335]
- ttenberg A, Geist TD. Animal model for investigating the anxiogenic effects of self-administered cocaine. *Psychopharmacology (Berl).* 1991; 103:455–461. [PubMed: 2062985]
- Fabre V, Beaufort C, Evrard A, Rioux A, Hanoun N, Lesch KP, Murphy DL, Lanfumey L, Hamon M, Martres MP. Altered expression and functions of serotonin 5-HT_{1A} and 5-HT_{1B} receptors in knock-out mice lacking the dopamine transporter. *Eur J Neurosci.* 2000; 12:19–26. [PubMed: 10651856]
- Freeman KB, Konaklieva MI, Riley AL. Assessment of the contributions of Na⁺ Channel inhibition and general peripheral action in cocaine-induced taste aversion. *Pharmacol Biochem Behav.* 2005a; 80:281–288. [PubMed: 15680181]
- Freeman KB, Rice KC, Riley AL. Assessment of monoamine transporter inhibition in the mediation of cocaine-induced conditioned taste aversion. *Pharmacol Biochem Behav.* 2005b; 82:583–589. [PubMed: 16337262]
- Freeman KB, Verendeev A, Riley AL. Noradrenergic antagonism enhances the conditioned aversive effects of cocaine. *Pharmacol Biochem Behav.* 2008; 88:523–532. [PubMed: 18045672]
- Gainetdinov RR, Caron MG. Monoamine transporters: from genes to behavior. *Ann Rev Pharmacol Toxicol.* 2003; 43:261–284. [PubMed: 12359863]
- arcia J, Kimeldorf DJ, Koelling RA. Conditioned aversion to saccharin resulting from exposure to gamma radiation. *Science.* 1955; 122:157–158. [PubMed: 14396377]
- Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. *Nature.* 1996; 379:606–612. [PubMed: 8628395]
- Goudie AJ, Thornton EW. Effects of drug experience on drug induced conditioned taste aversions: Studies with amphetamine and fenfluramine. *Psychopharmacologia.* 1975; 44:77–82. [PubMed: 1239032]
- Grigson PS. Conditioned taste aversions and drugs of abuse: A reinterpretation. *Behav Neurosci.* 1997; 111:129–136. [PubMed: 9109631]

- Grupp LA. Effects of pimozide on the acquisition, maintenance, and extinction of an amphetamine-induced taste aversion. *Psychopharmacology (Berl)*. 1997; 53:235–242. [PubMed: 408851]
- Hall FS, Li X, Sora I, Xu F, Caron M, Lesch KP, Murphy DL, Uhl GR. Cocaine Mechanism: enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions. *Neuroscience*. 2002; 115:153–161. [PubMed: 12401330]
- Hall FS, Sora I, Drgonova J, Li XF, Goeb M, Uhl GR. Molecular mechanism underlying the rewarding effects of cocaine. *Ann N Y Acad Sci*. 2004; 1025:47–56. [PubMed: 15542699]
- Hall FS, Li XF, Randall-Thompson J, Sora I, Murphy DL, Lesch KP, Caron M, Uhl GR. Cocaine-conditioned locomotion in dopamine transporter, norepinephrine transporter and 5-HT transporter knockout mice. *Neuroscience*. 2009 In Press.
- Hall FS, Sora I, Uhl GR. Ethanol consumption and reward are decreased in mu-opiate receptor knockout mice. *Psychopharmacology (Berl)*. 2001; 154:43–49. [PubMed: 11292005]
- Holmes A, Lit Q, Murphy DL, Gold E, Crawley JN. Abnormal anxiety-like behavior in serotonin transporter null mutant mice: the influence of genetic background. *Genes Brain Behav*. 2003a; 2:365–380. [PubMed: 14653308]
- Holmes A, Murphy DL, Crawley JN. Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety behavior. *Biol Psychiatry*. 2003b; 54:953–959. [PubMed: 14625137]
- Holmes A, Yang RJ, Murphy DL, Crawley JN. Evaluation of antidepressant-related behavioral response in mice lacking the serotonin transporter. *Neuropsychopharmacol*. 2002; 27:914–923.
- Hunt T, Amit Z. Conditioned taste aversion induced by self-administered drugs: paradox revisited. *Neurosci Biobehav Revs*. 1985; 22:945–948.
- Jones D, Hall FS, Uhl GR, Rice K, Riley AL. Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. *Pharmacol Biochem Behav*. 2009; 93:75–81. [PubMed: 19376154]
- Jones SR, Gainetdinov RR, Hu XT, Cooper DC, Wightman RM, White FJ, Caron MG. Loss of autoreceptor functions in mice lacking the dopamine transporter. *Nat Neurosci*. 1999; 2:649–655. [PubMed: 10404198]
- Kalueff AV, Fox MA, Gallagher PS, Murphy DL. Hypolocomotion anxiety and serotonin syndrome-like behavioral contribute to the complex phenotype of serotonin transporter Knockout mice. *Genes Brain Behav*. 2006; 6:389–400. [PubMed: 16939636]
- Kim DK, Tolliver TJ, Huang SJ, Martin BJ, Andrews AM, Ching S, Quan N, Stephens RL, Hill ER, Nottoli T, Han DD, Gu HH. Altered serotonin synthesis, turnover and dynamic regulation in multiple brain regions of mice lacking the serotonin transporter. *Neuropharmacol*. 2005; 49:798–810.
- Koob GF, Caine B, Parsons L, Markou A, Weiss F. Opponent process model of psychostimulant addiction. *Pharmacol Biochem Behav*. 1997; 57:514–527.
- Kuhar MJ, Ritz MC, Boja JW. The dopamine hypothesis of the reinforcing properties of cocaine. *Trends Neurosci*. 1991; 14:299–330. [PubMed: 1719677]
- Lynch WJ, Carroll ME. Regulation of drug intake. *Experimental and Clin Psychopharmacol*. 2001; 9:131–143.
- McDougle CJ, Black JE, Malison RT, Zimmermann RC, Kosten TR, Heninger GR, Price LH. Noradrenergic dysregulation during discontinuation of cocaine use in addicts. *Arch Gen Psychiatry*. 1994; 51:713–719. [PubMed: 8080348]
- Mead AN, Rocha BA, Donovan DM, Katz JL. Intravenous cocaine induced-activity and behavioral sensitization in norepinephrine-, but not dopamine-transporter knockout mice. *Eur J Neurosci*. 2002; 16:514–520. [PubMed: 12193195]
- Medvedev IO, Gainetdinov RR, Sotnikova TD, Bohn LM, Caron MG, Dykstra LA. Characterization of conditioned place preference to cocaine in congenic dopamine transporter knockout female mice. *Psychopharmacology (Berl)*. 2005; 180:408–413. [PubMed: 15719221]
- Mokrani MC, Duval F, Croca MA, Bailey P, Macher JP. HPA axis dysfunction in depression: correlation with monoamine system abnormalities. *Psychoneuroendocrinology*. 1997; 22:63–68.
- Milligan GP, Svoboda P, Brown CM. Why are there so many adrenoceptor subtypes? *Biochem Pharmacol*. 1994; 48:1059–1071. [PubMed: 7945399]

- Miner LL, Drago J, Chamberlain PM, Donovan D, Uhl GR. Retained cocaine conditioned place preference in D1 receptor deficient mice. *Neuroreport*. 1995; 6:2314–2316. [PubMed: 8747144]
- National Research Council. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press; 1996.
- National Research Council. Guide for the care and use of mammals in behavioral and neuroscience research. Washington, DC: National Academy Press; 2003.
- Pan YX, Xu J, Xu M, Rossi GC, Matulonis JE, Pasternak GW. Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions. *Proc Natl Acad Sci U S A*. 2009; 106:4917–4922. [PubMed: 19273844]
- Parker LA. Taste reactivity responses elicited by cocaine-, phencyclidine, and methamphetamine-paired sucrose solutions. *Behav Neurosci*. 1993; 107:118–129. [PubMed: 8447949]
- Paker LA. Rewarding drugs produce taste avoidance, but not taste aversion. *Neurosci Biobehav Rev*. 1995; 19:143–157. [PubMed: 7770194]
- Parsons LH, Weiss F, Koob GF. Serotonin1B receptor stimulation enhances cocaine reinforcement. *J Neurosci*. 1998; 18:10078–10089. [PubMed: 9822762]
- Pattij T, Broersen LM, van der Linde J, Groenink L, van der Gugten J, Maes RA, Olivier B. Operant learning and differential-reinforcement-of-low-rate 36-s responding in 5-HT1A and 5-HT1B receptor knockout mice. *Behav Brain Res*. 2003; 141:137–145. [PubMed: 12742250]
- Perona MT, Waters S, Hall FS, Sora I, Lesch KP, Murphy DL, Caron M, Uhl GR. Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions. *Behav Pharmacol*. 2008; 19:566–574. [PubMed: 18690111]
- Pruitt, DL; Bolanos, CA.; McDougall, SA. Effects of D1 and D2 receptor antagonists on cocaine-induced place preference in preweaning rats. *Eur J Pharmacol*. 1995; 283:125–131. [PubMed: 7498301]
- Randall-Thompson, JF. Dissertation Abstracts International. 2005. Characterization of dopamine and serotonin in concurrently conditioned taste aversion and place preferences.
- Riley, AL.; Simpson, GR. The attenuating effects of drug preexposure on taste aversion conditioning: Generality, experimental parameters, underlying mechanism and implications for drug use and abuse. In: Mower, RR.; Klein, SB., editors. *Contemporary learning theory*. 2nd Edition. Hillsdale, NJ: Lawrence Erlbaum Associates; 2001. p. 505-559.
- Riley AL, Tuck DL. Conditioned taste aversions: A behavioral index of toxicity. *Ann N Y Acad Sci*. 1985; 443:272–292. [PubMed: 2990284]
- Roberts DC, Fibiger HC. Attenuation of amphetamine-induced conditioned taste aversion following intraventricular 6-hydroxydopamine. *Neurosci Lett*. 1975; 1:343–347. [PubMed: 19604802]
- Rocha BA. Stimulant and reinforcing effects of cocaine in monoamine transporter knockout mice. *Euro J Pharmacol*. 2003; 479:107–115.
- ocha BA, Fumangalli F, Gainetdinov RR, Jones SR, Ator R, Giros B, Miller GW, Caron MG. Cocaine self-administration in dopamine-transporter knockout mice. *Nat Neurosci*. 1998; 1:132–137. [PubMed: 10195128]
- Rocha BA, Goulding EH, O'Dell LE, Mead AN, Coufal NG, Parsons LH, Tecott LH. Enhanced locomotor, reinforcing, and neurochemical effects of cocaine in serotonin 5-hydroxytryptamine 2C receptor mutant mice. *J Neurosci*. 2002; 22:10039–10045. [PubMed: 12427861]
- Rosen MI, Kosten TA. Cocaine-associated panic attacks in methadone-maintained patients. *Am J Drug Alcohol Abuse*. 1992; 18:57–62. [PubMed: 1314016]
- Serafine KM, Riley AL. Possible role of norepinephrine in cocaine-induced taste aversion. *Pharmacol Biochem Behav*. 2009; 92:111–116. [PubMed: 19027784]
- Shi WX, Pun CL, Zhang XX, Jones MD, Bunney BS. Dual effects of d-amphetamine on dopamine neurons mediated by dopamine and nordopamine receptors. *J Neurosci*. 2000; 20:3504–3511. [PubMed: 10777813]
- Shippenberg TS, Bals-Kubik R, Herz A. Examination of the neurochemical substrates mediating the motivational effects of opioid: Role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors. *J Pharmacol Exp Ther*. 1993; 265:53–59. [PubMed: 8386244]

- Sora I, Wichems C, Takahashi N, Li XF, Zeng Z, Revay R, Lesch KP, Murphy DL, Uhl GR. Cocaine reward models: Conditioned place preference can be established in dopamine and serotonin transporter knockout mice. *Proc Natl Acad Sci U S A*. 1998; 95:7699–7704. [PubMed: 9636213]
- Sora I, Hall FS, Andrews AM, Itokawa M, Li XF, Wei HB, Wichems C, Lesch KP, Murphy DL, Uhl GR. Molecular mechanisms of cocaine reward: Combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. *Proc Natl Acad Sci U S A*. 2001; 98:5003–5005.
- Stolerman IP, D'Mello GD. Role of training conditions in discrimination of central nervous system stimulants by rats. *Psychopharmacology (Berl)*. 1981; 73:295–303. [PubMed: 6113619]
- Tallarida, RJ.; Murray, RB. *Manual of pharmacologic calculations with computer programs*. Ed 2. New York: Springer; 1986.
- Taylor D, Ho BT. Comparison of inhibition of monoamine uptake by cocaine, methylphenidate and amphetamine. *Res Comm Chem Pathol Pharmacol*. 1978; 21:67–73.
- Thomsen M, Hall FS, Uhl GR, Caine SB. Dramatically decrease cocaine self administration in dopamine but not serotonin transporter knock-out mice. *J Neurosci*. 2009; 29:1087–1092.
- Tzavara ET, Degroot A, Wade MR, Davis RJ, Nomikos GG. CB1 receptor knockout mice are hyporesponsive to the behavior-stimulating actions of d-amphetamine: role of mGlu5 receptors. *Eur Neuropsychopharmacol*. 2009; 19:196–204. [PubMed: 19116182]
- Uhl GR, Hall FS, Sora I. Cocaine, reward movement and monoamine transporters. *Mol Psychiatry*. 2002; 7:21–26. [PubMed: 11803442]
- Wellman, Cl; Izquierdo, A.; Garrett, JE.; Martin, KP.; Carroll, J.; Millstein, R.; Lesch, KP.; Murphy, DL.; Holmes, A. Impaired stress-coping and fear extinction and abnormal corticolimbic morphology in serotonin knockout transporter knock-out mice. *J Neurosci*. 2007; 27:7–691.
- Woolverton WL, Kleven MS. Multiple dopamine receptors and the behavioral effects of cocaine. *NIDA Research Monograph*. 1988; 88:160–184. [PubMed: 3145448]
- Xu M, Guo Y, Vorhees CV, Zhang J. Behavioral responses to cocaine and amphetamine administration in mice lacking the dopamine D1 receptor. *Brain Res*. 200 a; 852:198–207. [PubMed: 10661513]
- Xu F, Gainetdinov RR, Wetsel WC. Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. *Nat. Neurosci*. 2000 b; 3:465–471. [PubMed: 10769386]
- Yang XM, Gorman AI, Dunn AJ, Goeders NE. Anxiogenic effects of acute and chronic cocaine administration: Neurochemical and behavioral studies of. *Pharmacol Biochem Behav*. 1992; 41:643–650. [PubMed: 1584846]

Figure 1.

Illustrates the Mean ($\pm$ SEM) Absolute Saccharin Consumption for D/S WT and NET WT After Conditioning with 0, 18, 32 or 50 mg/kg Doses of Cocaine. # Denotes significant difference from the saline-conditioned group.

Figure 2.
Illustrates the Mean ($\pm$ SEM) Absolute Saccharin Consumption for All Subjects Conditioned with Saline (0 mg/kg) on Conditioning Trials 1–4.

Figure 3.

Illustrates the Mean ($\pm$ SEM) Percent Decrease in Saccharin Consumption Between Trial 1 (Baseline) and Trials 2–4 for D/S WT and NET WT Subjects After Conditioning with 0, 18, 32 or 50 mg/kg Doses of Cocaine. # Denotes significant difference from the saline-conditioned control group of the same genotype

Figure 4.

Illustrates the Mean ($\pm$ SEM) Percent Decrease in Saccharin Consumption Between Trial 1 (Baseline) and Trials 2–4 for D/S WT, DAT KO and SERT KO Subjects After Conditioning with 0, 18, 32 or 50 mg/kg Doses of Cocaine. * Denotes significant difference from the WT group conditioned with the same dose. # Denotes significant difference from the saline-conditioned control group of the same genotype

Figure 5.

Illustrates the Mean ($\pm$ SEM) Percent Decrease in Saccharin Consumption Between Trial 1 (Baseline) and Trials 2–4 for NET WT, and NET KO Subjects After Conditioning with 0, 18, 32 or 50 mg/kg Doses of Cocaine. * Denotes significant difference from the WT group conditioned with the same dose. # Denotes significant difference from the saline-conditioned control group of the same genotype